Novel Carbohydrate Antiviral Drug Candidate Acts Through Galectin Inhibition to Block SARS-CoV-2 Coronavirus
Novel Carbohydrate Antiviral Drug Candidate Acts Through Galectin Inhibition to Block SARS-CoV-2 Coronavirus
ProLectin-M, a new class of oral antiviral drug
ProLectin-M, a新的班級 口頭的一個ti病毒藥物
BOSTON, MASSACHUSETTS, Aug. 01, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (Symbol: BIXT) (the "Company"), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral causing diseases announced today that the journal of International Journal of Health Sciences1 released a peer-reviewed article, "Carbohydrate ProLectin-M, a Galectin-3 Antagonist, Blocks SARS-CoV-2 Activity", that supports ProLectin-M's in vitro Mode of Action and the initial clinical data results reported in a previous article, referred to below. ProLectin-M is the Company's leading drug molecule in its pipeline to treat viral infections.
波士頓，馬薩諸塞州，2022年8月1日(Global Newswire)--BIOXYTRAN，Inc.(代碼：BIXT)(本公司)是一家臨牀階段生物技術公司，開發治療新冠肺炎和其他病毒性疾病的口服藥物。該公司今天宣佈，《國際健康科學雜誌》雜誌1發佈了一篇同行評議的文章，《Galectin-3拮抗劑碳水化合物ProLectin-M，阻斷SARS-CoV-2活性》，支持ProLectin-M的體外作用模式和前一篇文章中報告的初步臨牀數據結果，如下所述。ProLectin-M是該公司治療病毒感染的領先藥物分子。
The journal article begins to outline and further define the mechanism of action (MOA) behind the oral galectin inhibitor Prolectin-M. The article confirms and further expands on the preliminary clinical data results from Bioxytran's first peer-reviewed journal article in the Journal of Vaccines & Vaccination2, "Galectin Antagonist use in Mild Cases of SARS-CoV-2: Pilot Feasibility Randomised, Open Label, Controlled Trial", whereby human clinical trial results showed elimination of viral load to undetectable levels within a few days. The analytical tests within the scope of this most recent journal article utilize some of the most rigorously binding tests between a Lectin class of protein and carbohydrates.
這篇期刊文章開始概述並進一步定義口服Galectin抑制劑Prolectin-M背後的作用機制(MOA)。這篇文章證實並進一步擴展了Bioxtran在《疫苗與疫苗》雜誌上發表的第一篇同行評議期刊文章的初步臨牀數據結果2“Galectin拮抗劑在SARS-CoV-2輕度病例中的使用：飛行員隨機、開放標籤、對照試驗的可行性”，人體臨牀試驗結果顯示，病毒載量在幾天內消除到無法檢測的水平。這篇最新期刊文章範圍內的分析測試利用了凝集素類蛋白質和碳水化合物之間最嚴格的結合測試。
1)
1)
2)
2)
About Bioxytran, Inc.
Bioxytran, Inc. is a clinical stage biotechnology company developing novel therapies targeting the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia. The leading drug candidate, Prolectin-M, is a new class of antiviral drug designed to antagonize galectins implicated in inflammatory, fibrotic, and malignant diseases and bind to the conserved region of the spike protein commonly known as the galectin fold. Bioxytran's other development programs are for pulmonary fibrosis and stroke treatment. More information can be found at
Bioxtran公司簡介
Bioxtran，Inc.是一家臨牀階段的生物技術公司，開發新的療法，旨在治療病毒學、退行性疾病和缺氧方面尚未得到滿足的重大醫療需求。主要候選藥物Prolectin-M是一種新型抗病毒藥物，旨在拮抗與炎症、纖維化和惡性疾病有關的Galectins，並與通常稱為Galectin摺疊的刺突蛋白的保守區結合。Bioxtran的其他開發項目是肺纖維化和中風治療。欲瞭解更多信息，請訪問
About Galectins
Galectins are carbohydrate-binding proteins that are involved in many physiological functions, such as inflammation, immune responses, cell migration, autophagy, and signaling. They are also linked to diseases such as fibrosis, cancer and heart disease.
關於Galectins
Galectins是一種碳水化合物結合蛋白，參與許多生理功能，如炎症、免疫反應、細胞遷移、自噬和信號轉導。它們還與纖維化、癌症和心臟病等疾病有關。
About Lectins
Galectins are a class of specific lectins. Lectins are a special class of proteins widely distributed in nature, which selectively recognize and reversibly bind to carbohydrates and glycoconjugates through their binding sites. These proteins, which can be detected through hemagglutination assays, interact with different carbohydrates present in cell and viral surfaces.
關於凝集素
半乳糖凝集素是一類特定的凝集素。凝集素是一類廣泛分佈於自然界的特殊蛋白質，它通過結合部位選擇性地識別並可逆地與碳水化合物和糖共軛結合。這些蛋白質可以通過血凝試驗檢測到，它們與細胞和病毒表面存在的不同碳水化合物相互作用。
About ProLectin-M
ProLectin-M is an orally administered experimental new drug candidate that targets the Carbohydrate Binding Domain portion on the SARS-CoV-2, coronavirus. ProLectin-M is expected to interfere with the binding of the virus to the cell and thereby prevent viral entry into cells. Preclinical in-vitro and in-vivo preliminary data shows that ProLectin-M is non-toxic for humans. ProLectin-M was used in an open label, randomized, controlled clinical feasibility study in COVID-19 patients with mild-to-moderate COVID-19 disease.
關於ProL凝集素-M
ProLectin-M是一種口服試驗性新藥候選藥物，針對SARS-CoV-2冠狀病毒上的碳水化合物結合結構域部分。ProLectin-M有望幹擾病毒與細胞的結合，從而阻止病毒進入細胞。臨牀前、體外和體內初步數據顯示，ProLectin-M對人體無毒。ProLectin-M用於一項開放標籤、隨機、對照的新冠肺炎輕中度新冠肺炎病患者的臨牀可行性研究。
Investor Relations
Michael Sheikh
509-991-0245
投資者關係
邁克爾·謝赫
509-991-0245
mike.sheikh@bioxytraninc.com
郵箱：mike.sheikh@bioxtraninc.com
Forward-Looking Statements
轉發看起來像是報表
This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words "believe," "expect," "anticipate," "estimate," "intend," "plan," and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran's actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.
本新聞稿包括聯邦法律規定的前瞻性陳述，包括本新聞稿中描述的與技術性能有關的陳述。這些前瞻性表述通常由“相信”、“預期”、“預期”、“估計”、“打算”、“計劃”以及類似的表述來識別，儘管並不是所有前瞻性表述都包含這些可識別的詞語。此類陳述會受到重大風險、假設和不確定性的影響。已知的可能導致Bioxtran的實際結果與這些前瞻性陳述預期的結果大不相同的重大因素在前瞻性陳述中描述，風險因素在公司截至2021年12月31日的財政年度的Form 10-K年度報告中描述，這些風險因素在提交給美國證券交易委員會的其他文件中不時列出。除聯邦證券法要求的範圍外，Bioxtran沒有義務糾正或更新任何前瞻性陳述，無論是由於新信息、未來事件或其他原因。
譯文內容由第三人軟體翻譯。